# Tenofovir Alafenamide and Its Impact on the Epigenetic Clock in Healthy Adults

Canonical source: https://retacompare.com/research/tenofovir-alafenamide-and-its-impact-on-the-epigenetic-clock-in-healthy-adults

Epigenetic Aging · 2026-03-26


    A recent study indicates that Tenofovir Alafenamide (TAF) may reduce biological age as measured by the epigenetic clock in healthy adults. This research suggests that certain antiretroviral therapies, typically used for HIV treatment, may have applications in gerotherapeutics by targeting age-associated biological markers. By focusing on DNA methylation profiles, the study provides insights into how these therapies could influence healthspan and longevity.

 What this study examined

The study evaluated the effects of two different nucleos(t)ide reverse transcriptase inhibitors (NRTIs), specifically emtricitabine-tenofovir-alafenamide (FTC/TAF) and emtricitabine-tenofovir-disoproxil fumarate (FTC/TDF), on biological aging in healthy adults aged 18-50. Conducted over 12 weeks, the research involved two randomized, directly observed dosing pharmacokinetic studies. The primary outcome measured was the change in DNA methylation-based biological aging markers, which included various epigenetic clocks such as DunedinPACE and PhenoAge.

 Why this matters for longevity research

Understanding how TAF affects the epigenetic clock is crucial for longevity research, as biological age is increasingly recognized as a significant predictor of healthspan. The results suggest that TAF may suppress age-associated retrotransposon activity, which is linked to various age-related diseases. This aligns with the growing interest in gerotherapeutics—therapies aimed at targeting the biological mechanisms of aging—offering a potential avenue for extending healthspan and improving quality of life in aging populations.

 Key findings

The FTC/TAF regimen resulted in a significant decrease in biological age measures, including DunedinPACE and PhenoAge.

Participants in the FTC/TAF group showed concordant reductions in additional epigenetic clocks estimating brain aging.

There were notable declines in epigenetic markers associated with inflammation, including IL-6 and a trend toward reduced C-reactive protein.

No significant changes were observed in the FTC/TDF group, highlighting differences in cellular pharmacology between the two treatments.

The study supports the hypothesis that TAF may have gerotherapeutic effects due to its favorable pharmacological profile.

Further research is warranted to explore these findings in larger, placebo-controlled studies.

 The science behind it

The underlying mechanism of how TAF influences the epigenetic clock may relate to its ability to modulate retrotransposon activity, which can impact genomic stability and inflammation. Epigenetic clocks, such as those based on DNA methylation, serve as biomarkers of biological age, reflecting the cumulative effects of environmental and lifestyle factors on gene expression. By potentially reducing inflammatory markers and stabilizing the genome, TAF may contribute to healthier aging, aligning with theories of aging that emphasize the importance of maintaining cellular integrity and function.

 How it fits into the longevity field

This study adds to a growing body of literature examining the intersection of antiviral therapies and aging biology. Similar to other interventions targeting the epigenetic clock, such as NAD+ precursors and sirtuin activators, TAF represents a novel approach to gerotherapeutics. The implications of this research extend to various fields, including geroscience and age-related disease prevention, suggesting that existing medications may be repurposed to enhance healthspan.

 Practical takeaways

Researchers and informed readers should consider the potential of existing antiretroviral therapies like TAF in the context of aging research. The findings underscore the importance of exploring how medications can influence biological aging and healthspan. Future studies should focus on validating these results and investigating the mechanisms at play, which may lead to new therapeutic strategies aimed at extending healthy lifespan.

 FAQ

 What is the epigenetic clock?

The epigenetic clock refers to biomarkers, particularly DNA methylation patterns, that can predict biological age and health status.

 How does Tenofovir Alafenamide work?

Tenofovir Alafenamide is an antiviral medication that inhibits reverse transcriptase, reducing viral replication and potentially influencing aging-related biological markers.

 What are gerotherapeutics?

Gerotherapeutics are treatments designed to target the biological mechanisms of aging, aiming to extend healthspan and improve quality of life.

 Source: PubMed · medRxiv · published 2026-03-26.

## Sources

- PubMed · medRxiv: https://pubmed.ncbi.nlm.nih.gov/41929344/